Scientific References Check out the scientific literature that supports our molecular targets and our synthetic lethal approach. June 2024 Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study) Zev A Wainberg, Et Al. ESMO Gastrointestinal Cancers Annual Congress 2024 - Abstract 504MO June 2024 Characterizing intra-tumoral heterogeneity of CCNE1 amplification in ovarian cancer using digital pathology Adam Petrone, Isabel Soria-Bretones, Adrienne Johnson, Et Al. AACR SPECIAL CONFERENCE IN CANCER RESEARCH: EXPANDING AND TRANSLATING CANCER SYNTHETIC VULNERABILITIES May 2024 Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib Robert Papp, Laird Trimble, Adrian J. Fretland, et al. Drug Metabolism and Disposition May 2024 ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) Elisa Fontana, MD, PhD, Ezra Rosen, MD, PhD, et al. Journal of the National Cancer Institute April 2024 Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas Michael S. Nakazawa, Ian M. Silverman, Victoria Rimkunas, Et Al. Molecular Cancer Therapeutics April 2024 Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma Meredith S. Pelster, Ian M. Silverman, Joseph D. Schonhoft, Et Al. npj Precision Oncology January 2024 Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials Ian M. Silverman, Joseph D. Schonhoft, et al. AACR Special Conference in Cancer Research: DNA Damage Repair January 2024 Identification of monoallelic ATM loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy Stephanie Lheureux, Joseph D. Schonhoft, et al. AACR Special Conference in Cancer Research: DNA Damage Repair January 2024 Exceptional response to the ataxia telangiectasia and Rad3-related inhibitor (ATRi), camonsertib, in a patient with alternative lengthening of telomeres (ALT)-positive metastatic melanoma Timothy A. Yap, Ian M. Silverman, et al. AACR Special Conference in Cancer Research: DNA Damage Repair October 2023 KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition Marc L. Hyer, Jimmy Fourtounis, Et Al. AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS 1234 We have a number of synthetic lethal therapies in development. View Pipeline
